A diimmistration of a variety of noonfibrinolytic, noanenizymImatic substances imdluces fibrinmolvsis in moan. The most potent materials of this type known at present are purified protein-fre( pyrogenms. Their action after intravenous injection on the huiman fibrinolytic system, on some of its componemIts, and on the clotting system of 67 individuals has been studied. The possible therapeutic i...

Stroke is relatively rare in children, but can lead to significant morbidity and mortality. Understanding that children with strokes present differently than adults and often present with unique risk factors will optimize outcomes in children. Despite an increased incidence of pediatric stroke, there is often a delay in diagnosis, and cases may still remain under- or misdiagnosed. Clinical pres...

This article describes the methodology for the Seventh American College of Chest Physicians (ACCP) Conference on Antithrombotic and Thrombolytic Therapy: Evidence-Based Guidelines. Guideline authors began by specifying the population, the intervention and alternative, and the outcomes for each clinical question, and defined the criteria for eligible articles, including methodological criteria, ...

A facile synthetic route of rivaroxaban has been developed. Using commercially available (R)-epichlorohydrin and bromobenzene as the starting materials, rivaroxaban was obtained in 39% overall yield using a Goldberg coupling as the key step. The synthetic route represents a convenient procedure for the production of rivaroxaban.

As an interventional cardiologist and a clinical trialist, I am often asked, “what do we need to do to improve mortality by another 1% in the setting of acute myocardial infarction?” Indeed, nearly a decade and a half of effort and many hundreds of millions of dollars have been spent in pursuit of this elusive “1% reduction” in mortality by both the pharmaceutical and the device industry. As th...

When the aim of the randomized controlled trial (RCT) is to show that one treatment is superior to another, a statistical test is employed and the trial (test) is called a superiority trial (test). Often a nonsignificant superiority test is wrongly interpreted as proof of no difference between the two treatments. Proving that two treatments are equal in performance is impossible with statistica...

Early reperfusion therapy has proved beneficial in such infarctions. 2-4 The earlier the reperfusion, the greater the benefit, and the time to treatment is now considered to indicate the quality of care. These days, when thrombolytic treatment and percutaneous intervention are carried out so readily, it is important to remember that acute infarction is not the only cause of ST-segment elevation...